ethyl 4-({[3-(benzyloxy)phenyl]methyl}amino)benzoate | 64518-67-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 4-({[3-(benzyloxy)phenyl]methyl}amino)benzoate
• 英文别名: Ethyl 4-[(3-phenylmethoxyphenyl)methylamino]benzoate
• CAS: 64518-67-8
• 化学式: C₂₃H₂₃NO₃
• 分子量: 361.441
• InChiKey: APKNIYWLCMTUKZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  对联苯磺酰氯 、 ethyl 4-({[3-(benzyloxy)phenyl]methyl}amino)benzoate 在 吡啶 、 4-二甲氨基吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以71%的产率得到ethyl 4-(N-{[3-(benzyloxy)phenyl]methyl}[1,1’-biphenyl]-4-sulfonamido)benzoate
  参考文献：
  名称：

  Discovery of a benzenesulfonamide-based dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase that favorably modulates lipid mediator biosynthesis in inflammation

  摘要：

  Leukotrienes (LTs) and prostaglandin (PG)E-2, produced by 5-lipoxygenase (5-LO) and microsomal prostaglandin E-2 synthase-1 (mPGES-1), respectively, are key players in inflammation, and pharmacological suppression of these lipid mediators (LM) represents a strategy to intervene with inflammatory disorders. Previous studies revealed that the benzenesulfonamide scaffold displays efficient 5-LO-inhibitory properties. Here, we structurally optimized benzenesulfonamides which led to an N-phenyl-benzenesulfonamide derivative (compound 47) with potent inhibitory activities (IC50 = 2.3 and 0.4 mu M for isolated 5-LO and 5-LO in intact cells, respectively). Compound 47 prevented the interaction of 5-LO with its activating protein (FLAP) at the nuclear envelope in transfected HEK293 cells as shown by in situ proximity ligation assay. Comprehensive assessment of the LM profile produced by human macrophages revealed the ability of 47 to selectively down-regulate pro-inflammatory LMs (i.e. LTs and PGE(2)) in M1 but to enhance the formation of pro-resolving LMs (i.e. resolvins and maresins) in M2 macrophages. Moreover, 47 strongly inhibited LT formation and cell infiltration in two in vivo models of acute inflammation (i.e., peritonitis and air pouch sterile inflammation in mice). Together, 47 represents a novel LT biosynthesis inhibitor with an attractive pharmacological profile as anti-inflammatory drug that also promotes the biosynthesis of pro-resolving LM. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.07.031
• 作为产物：
  描述：

  3-苄氧基苯甲醛 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 20.0h， 生成 ethyl 4-({[3-(benzyloxy)phenyl]methyl}amino)benzoate
  参考文献：
  名称：

  Discovery of a benzenesulfonamide-based dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase that favorably modulates lipid mediator biosynthesis in inflammation

  摘要：

  Leukotrienes (LTs) and prostaglandin (PG)E-2, produced by 5-lipoxygenase (5-LO) and microsomal prostaglandin E-2 synthase-1 (mPGES-1), respectively, are key players in inflammation, and pharmacological suppression of these lipid mediators (LM) represents a strategy to intervene with inflammatory disorders. Previous studies revealed that the benzenesulfonamide scaffold displays efficient 5-LO-inhibitory properties. Here, we structurally optimized benzenesulfonamides which led to an N-phenyl-benzenesulfonamide derivative (compound 47) with potent inhibitory activities (IC50 = 2.3 and 0.4 mu M for isolated 5-LO and 5-LO in intact cells, respectively). Compound 47 prevented the interaction of 5-LO with its activating protein (FLAP) at the nuclear envelope in transfected HEK293 cells as shown by in situ proximity ligation assay. Comprehensive assessment of the LM profile produced by human macrophages revealed the ability of 47 to selectively down-regulate pro-inflammatory LMs (i.e. LTs and PGE(2)) in M1 but to enhance the formation of pro-resolving LMs (i.e. resolvins and maresins) in M2 macrophages. Moreover, 47 strongly inhibited LT formation and cell infiltration in two in vivo models of acute inflammation (i.e., peritonitis and air pouch sterile inflammation in mice). Together, 47 represents a novel LT biosynthesis inhibitor with an attractive pharmacological profile as anti-inflammatory drug that also promotes the biosynthesis of pro-resolving LM. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.07.031

文献信息

• DE2701854
  申请人：——

  公开号：——

  公开（公告）日：——
• Discovery of a benzenesulfonamide-based dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase that favorably modulates lipid mediator biosynthesis in inflammation
  作者：Sun-Yee Cheung、Markus Werner、Lucia Esposito、Fabiana Troisi、Vincenza Cantone、Stefanie Liening、Stefanie König、Jana Gerstmeier、Andreas Koeberle、Rossella Bilancia、Roberta Rizza、Antonietta Rossi、Fiorentina Roviezzo、Veronika Temml、Daniela Schuster、Hermann Stuppner、Manfred Schubert-Zsilavecz、Oliver Werz、Thomas Hanke、Simona Pace

  DOI：10.1016/j.ejmech.2018.07.031

  日期：2018.8

  Leukotrienes (LTs) and prostaglandin (PG)E-2, produced by 5-lipoxygenase (5-LO) and microsomal prostaglandin E-2 synthase-1 (mPGES-1), respectively, are key players in inflammation, and pharmacological suppression of these lipid mediators (LM) represents a strategy to intervene with inflammatory disorders. Previous studies revealed that the benzenesulfonamide scaffold displays efficient 5-LO-inhibitory properties. Here, we structurally optimized benzenesulfonamides which led to an N-phenyl-benzenesulfonamide derivative (compound 47) with potent inhibitory activities (IC50 = 2.3 and 0.4 mu M for isolated 5-LO and 5-LO in intact cells, respectively). Compound 47 prevented the interaction of 5-LO with its activating protein (FLAP) at the nuclear envelope in transfected HEK293 cells as shown by in situ proximity ligation assay. Comprehensive assessment of the LM profile produced by human macrophages revealed the ability of 47 to selectively down-regulate pro-inflammatory LMs (i.e. LTs and PGE(2)) in M1 but to enhance the formation of pro-resolving LMs (i.e. resolvins and maresins) in M2 macrophages. Moreover, 47 strongly inhibited LT formation and cell infiltration in two in vivo models of acute inflammation (i.e., peritonitis and air pouch sterile inflammation in mice). Together, 47 represents a novel LT biosynthesis inhibitor with an attractive pharmacological profile as anti-inflammatory drug that also promotes the biosynthesis of pro-resolving LM. (C) 2018 Elsevier Masson SAS. All rights reserved.